Conditions: HIV-1 Infection Neuropathic Pain
Keywords: peripheral neuropathic pain pregabalin safety
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 217
Healthy volunteers: no

Brief summary:
This study examines the safety of pregabalin over a 6 month period in patients with neuropathic pain associated with HIV infection as an extension of another trial that tests the efficacy of pregabalin.

Detailed description:
The parent double blind study was stopped at interim analysis due to lack of efficacy and therefore this open label extension study was also terminated simultaneously on April 2, 2012; the termination was unrelated to any safety findings that could impact patient health.

Arms:
arm 1: None

Interventions: intervention 1: pregabalin (Lyrica)
Intervention descriptions: intervention 1: 150 mg-600 mg/day (twice daily)

Protocol document: